Upstream Bio presented additional Phase 2 VIBRANT trial data showing verekitug reduced nasal polyp scores and congestion in chronic rhinosinusitis patients, while Phase 2 VALIANT trial results demonstrated significant reductions in asthma exacerbations with multiple dosing regimens.
The European Commission has approved GSK's Exdensur (depemokimab) as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, offering twice-yearly dosing based on positive phase 3 trial results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07341776 |
Steroid Use in Treatment of Allergic Reactions to Food |
RECRUITING | PHASE4 |
| NCT07328984 |
How Long Should we Give Steroids for Patients With Severe PCP |
NOT_YET_RECRUITING | PHASE4 |
| NCT07113834 |
Characteristics of Ankylosing Spondylitis Associated Uveitis |
COMPLETED | |
| NCT02406651 |
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD |
COMPLETED | PHASE1/PHASE2 |
| NCT01079988 |
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence |
COMPLETED | PHASE4 |
